ECDI-fixed allogeneic splenocytes combined with α1-antitrypsin prolong survival of rat renal allografts

International Immunopharmacology
Guodong ChenJiang Qiu

Abstract

Pre- and post-transplant infusions of donor splenocytes treated with 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide (ECDI-SPs) induce donor-specific tolerance and prolong rat renal allograft survival. However, proinflammatory cytokine production during peritransplantation negates the effects of ECDI-SPs. Therefore, we reasoned that blocking proinflammatory cytokines would promote long-term ECDI-SP-induced allograft survival. We therefore examined the effects of infusing ECDI-SPs alone or in combination with a short course of α1-Antitrypsin (AAT) on the long-term outcomes of a rat kidney allograft model. The data showed that ECDI-SPs+AAT promote renal allograft survival compared with ECDI-SPs alone. This effect was accompanied by expansion of Foxp3+ Tregs, enhanced alloantigen-specific Treg function, and modulation of expression levels of proinflammatory cytokines IL-1β, IL-6, TNF-α, and the anti-inflammatory cytokine IL-10. In conclusion, our strategy of combining ECDI-SPs and AAT provides a promising approach for inducing specific transplant tolerance.

References

Nov 25, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Dongmei ChenJonathan S Bromberg
Oct 20, 2004·The Journal of Experimental Medicine·Alena M Gallegos, Michael J Bevan
May 10, 2005·Proceedings of the National Academy of Sciences of the United States of America·Sifeng ChenAnupam Agarwal
Nov 23, 2006·The Journal of Experimental Medicine·Brian T FifeJeffrey A Bluestone
Apr 26, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·B ChenS Chen
Aug 11, 2007·Nature Reviews. Immunology·Stephen D MillerJoseph R Podojil
Sep 18, 2008·Proceedings of the National Academy of Sciences of the United States of America·Xunrong LuoStephen D Miller
Oct 15, 2008·Proceedings of the National Academy of Sciences of the United States of America·Eli C LewisCharles A Dinarello
Oct 15, 2008·Proceedings of the National Academy of Sciences of the United States of America·Maria KoulmandaTerry B Strom
Apr 14, 2011·Orphanet Journal of Rare Diseases·Ignacio BlancoFrederick de Serres
Nov 22, 2011·Transplantation Proceedings·L KrishnanS K Williams
Feb 22, 2012·Archivum Immunologiae Et Therapiae Experimentalis·David A BerginEmer P Reeves
Aug 14, 2012·Expert Review of Clinical Immunology·Steven Goldstein, Pavan Reddy
Aug 14, 2012·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·G ChenX Luo
Apr 13, 2013·Clinical Journal of the American Society of Nephrology : CJASN·Behdad AfzaliGiovanna Lombardi
Dec 25, 2013·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Wenxi GaoMingyao Liu
Mar 22, 2014·Clinical Reviews in Allergy & Immunology·Cheng ZhangXing-Hua Chen

❮ Previous
Next ❯

Citations

Dec 1, 2017·Current Opinion in Organ Transplantation·Natalie A O'NeillJonathan S Bromberg
Oct 11, 2016·Cellular & Molecular Immunology·Rita DiehlJohannes Boltze

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.